Chinese Journal of Stroke ›› 2023, Vol. 18 ›› Issue (8): 867-872.DOI: 10.3969/j.issn.1673-5765.2023.08.003
Previous Articles Next Articles
ZHANG Dongling, WU Tao
Received:
2023-08-08
Online:
2023-08-20
Published:
2023-08-20
张冬玲,吴涛
通讯作者:
吴涛 wutao69@163.com
基金资助:
ZHANG Dongling, WU Tao. Advances of Imaging in the Differential Diagnosis of Vascular Parkinsonism[J]. Chinese Journal of Stroke, 2023, 18(8): 867-872.
张冬玲, 吴涛. 血管性帕金森综合征鉴别诊断的影像学研究进展[J]. 中国卒中杂志, 2023, 18(8): 867-872.
[1] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国血管性帕金森综合征诊断与治疗专家共识[J]. 中华神经科杂志,2017,50(5):326-331. Parkinson’s Disease & Movement Disorders Society,Chinese Society of Neurology,Parkinson’s Disease & Movement Disorders Society,Chinese Neurology Association. Chinese experts’consensus of diagnosis and treatment of vascular parkinsonism[J]. Chin J Neurol,2017,50(5):326-331. [2] VALE T C,CARAMELLI P,CARDOSO F. Clinicoradiological comparison between vascular parkinsonism and Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry,2015,86(5):547-553. [3] KORCZYN A D. Vascular parkinsonism--characteristics,pathogenesis and treatment[J]. Nat Rev Neurol,2015,11(6):319-326. [4] KALRA S,GROSSET D G,BENAMER H T. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease:a systematic review[J]. Mov Disord,2010,25(2):149-156. [5] SCHUEPBACH W M,RAU J,KNUDSEN K,et al. Neurostimulation for Parkinson’s disease with early motor complications[J]. N Engl J Med,2013,368(7):610-622. [6] SHIH L C,TARSY D. Deep brain stimulation for the treatment of atypical parkinsonism[J]. Mov Disord,2007,22(15):2149-2155. [7] SHIN H W,HONG S W,YOUN Y C. Clinical aspects of the differential diagnosis of Parkinson’s disease and parkinsonism[J]. J Clin Neurol,2022,18(3):259-270. [8] RACCAGNI C,NONNEKES J,BLOEM B R,et al. Gait and postural disorders in parkinsonism:a clinical approach[J]. J Neurol,2020,267(11):3169-3176. [9] NARASIMHAN M,SCHWARTZ R,HALLIDAY G. Parkinsonism and cerebrovascular disease[J/OL]. J Neurol Sci,2022,433:120011[2023-02-15]. https://doi.org/10.1016/j.jns.2021.120011. [10] KALRA S,GROSSET D G,BENAMER H T. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease:a systematic review[J]. Mov Disord,2010,25(2):149-156. [11] VALE T C,CARAMELLI P,CARDOSO F. Clinicoradiological comparison between vascular parkinsonism and Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry,2015,86:547-553. [12] KIM J S. Involuntary movements after anterior cerebral artery territory infarction[J]. Stroke,2001,32(1):258-261. [13] ZIJLMANS J C. The role of imaging in the diagnosis of vascular parkinsonism[J]. Neuroimaging Clin N Am,2010,20(1):69-76. [14] BOHNEN N I,ALBIN R L. White matter lesions in Parkinson disease[J]. Nat Rev Neurol,2011,7(4):229-236. [15] DE OLIVEIRA P,MARTINS B J,CARDOSO F E C. White matter hyperintensity presence,quantity,and location exhibits no association with motor and non-motor manifestations of PD[J/OL]. Parkinsonism Relat Disord,2023,106:105245[2023-02-10]. https://doi.org/10.1016/j.parkreldis.2022.105245. [16] MA K K Y,LIN S,MOK V C T. Neuroimaging in vascular parkinsonism[J/OL]. Curr Neurol Neurosci Rep,2019,19(12):102[2023-02-11]. https://doi.org/10.1007/s11910-019-1019-7. [17] DUNET V,DEVERDUN J,CHARROUD C,et al. MRI volumetric morphometry in vascular parkinsonism[J]. J Neurol,2017,264(7):1511-1519. [18] CHOI S M,KIM B C,NAM T S,et al. Midbrain atrophy in vascular parkinsonism[J]. Eur Neurol,2011,65(5):296-301. [19] MOSTILE G,NICOLETTI A,CICERO C E,et al. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism[J]. Neurol Sci,2016,37(4):591-595. [20] QUATTRONE A,BIANCO M G,ANTONINI A,et al. Development and validation of automated magnetic resonance parkinsonism index 2.0 to distinguish progressive supranuclear palsy-parkinsonism from Parkinson’s disease[J]. Mov Disord,2022,37(6):1272-1281. [21] KIM B C,CHOI S M,CHOI K H,et al. MRI measurements of brainstem structures in patients with vascular parkinsonism,progressive supranuclear palsy,and Parkinson’s disease[J]. Neurol Sci,2017,38(4):627-633. [22] BENVENISTE H,ELKIN R,HEERDT P M,et al. The glymphatic system and its role in cerebral homeostasis[J]. J Appl Physiol,2020,129(6):1330-1340. [23] TROILI F,CIPOLLINI V,MOCI M,et al. Perivascular Unit:this must be the place. The anatomical crossroad between the immune,vascular and nervous system[J/OL]. Front Neuroanat,2020,14:17[2023-02-10]. https://doi.org/10.3389/fnana.2020.00017. [24] TU Y,ZHUO W Y,PENG J W,et al. The correlation between enlarged perivascular spaces and cognitive impairment in Parkinson’s disease and vascular parkinsonism[J]. BMC Neurol,2022,22(1):282. [25] WANG H C,HSU J L,LEEMANS A. Diffusion tensor imaging of vascular parkinsonism:structural changes in cerebral white matter and the association with clinical severity[J]. Arch Neurol,2012,69(10):1340-1348. [26] MANIEGA S M,VALDÉS HERNÁNDEZ M C,CLAYDEN J D,et al. White matter hyperintensities and normal appearing white matter integrity in the aging brain[J]. Neurobiol Aging,2015,36(2):909-918. [27] SALSONE M,CALIGIURI M E,VESCIO V,et al. Microstructural changes of normal-appearing white matter in vascular parkinsonism[J/OL]. Parkinsonism Relat Disord,2019,63:60-65[2023-02-10]. https://doi.org/10.1016/j.parkreldis.2019.02.046. [28] WISE R M,WAGENER A,FIETZEK U M,et al. Interactions of dopamine,iron,and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson’s disease and neurodegeneration with brain iron accumulation disorders[J/OL]. Neurobiol Dis,2022,175:105920[2023-02-10]. https://doi.org/10.1016/j.nbd.2022.105920. [29] HALLER S,HAACKE E M,THURNHER M M,et al. Susceptibility-weighted Imaging:technical essentials and clinical neurologic applications[J]. Radiology,2021,299(1):3-26. [30] BAE Y J,KIM J M,KIM E,et al. Loss of nigral hyperintensity on 3 tesla MRI of parkinsonism:comparison with 123I-FP-CIT SPECT[J]. Mov Disord,2016,31(5):684-692. [31] ZHAO X J,NIU X Y,YOU H Y,et al. Signal alteration of substantia nigra on 3. 0T susceptibility-weighted imaging in Parkinson’s Disease and vascular parkinsonism[J]. Curr Med Sci,2019,39(5):831-835. [32] MARTIN-BASTIDA A,PIETRACUPA S,PICCINI P. Neuromelanin in parkinsonian disorders:an update[J]. Int J Neurosci,2017,127(12):1116-1123. [33] HE N Y,CHEN Y S,LEWITT P A,ET AL. Application of neuromelanin MR imaging in Parkinson Disease[J]. J Magn Reson Imaging,2023,57(2):337-352. [34] NOBILEAU A,GAURAV R,CHOUGAR L,et al. Neuromelanin-sensitive magnetic resonance imaging changes in the locus coeruleus/subcoeruleus complex in patients with typical and atypical Parkinsonism[J]. Mov Disord,2023,38(3):479-484. [35] WANG E W,BROWN G L,LEWIS M M,et al. Susceptibility magnetic resonance imaging correlates with glial density and tau in the substantia nigra pars compacta[J]. Mov Disord,2023,38(3):464-473. [36] MATSUURA K,II Y,MAEDA M,et al. Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia[J/OL]. Parkinsonism Relat Disord,2021,87:75-81[2023-02-01]. https://doi.org/10.1016/j.parkreldis.2021.05.002. [37] GOLAN H,VOLKOV O,SHALOM E. Nuclear imaging in Parkinson’s disease:the past,the present,and the future[J/OL]. J Neurol Sci,2022,436:120220[2023-02-15]. https://doi.org/10.1016/j.jns.2022.120220. [38] WALLERT E D,VAN DE GIESSEN E,KNOL R J J,et al. Imaging dopaminergic neurotransmission in neurodegenerative disorders[J]. J Nucl Med,2022,63(Suppl 1):27S-32S. [39] PARK D G,KANG S Y,HONG J Y,et al. Factors associated with motor severity in vascular parkinsonism with normal dopamine transporter imaging[J]. Parkinsonism Relat Disord,2022,94:99-103. [40] BENITEZ-RIVERO S,MARÍN-OYAGA V A,GARCÍA-SOLÍS D,et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry,2013,84(2):122-129. [41] SOLLA P,CANNAS A,ARCA R,et al. Focal 123I-FP-CIT SPECT abnormality in midbrain vascular parkinsonism[J/OL]. Case Rep Neurol Med,2015,2015:642764[2023-02-15]. https://doi.org/10.1155/2015/642764. [42] ZIJLMANS J,EVANS A,FONTES F,et al. 123I FP-CIT spect study in vascular parkinsonism and Parkinson’s disease[J]. Mov Disord,2007,22(9):1278-1285. [43] BOOTH T C,NATHAN M,WALDMAN A D,et al. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes,part 1[J]. AJNR Am J Neuroradiol,2015,36:229-235. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||